JP2023505708A5 - - Google Patents

Info

Publication number
JP2023505708A5
JP2023505708A5 JP2022535591A JP2022535591A JP2023505708A5 JP 2023505708 A5 JP2023505708 A5 JP 2023505708A5 JP 2022535591 A JP2022535591 A JP 2022535591A JP 2022535591 A JP2022535591 A JP 2022535591A JP 2023505708 A5 JP2023505708 A5 JP 2023505708A5
Authority
JP
Japan
Prior art keywords
seq
represented
variable region
chain variable
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022535591A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023505708A (ja
JP7720305B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2020/135680 external-priority patent/WO2021115426A1/zh
Publication of JP2023505708A publication Critical patent/JP2023505708A/ja
Publication of JP2023505708A5 publication Critical patent/JP2023505708A5/ja
Application granted granted Critical
Publication of JP7720305B2 publication Critical patent/JP7720305B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022535591A 2019-12-12 2020-12-11 抗クローディン抗体薬物複合体及びその医薬用途 Active JP7720305B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201911273041.7 2019-12-12
CN201911273041 2019-12-12
CN202011060513 2020-09-30
CN202011060513.3 2020-09-30
PCT/CN2020/135680 WO2021115426A1 (zh) 2019-12-12 2020-12-11 抗密蛋白抗体药物偶联物及其医药用途

Publications (3)

Publication Number Publication Date
JP2023505708A JP2023505708A (ja) 2023-02-10
JP2023505708A5 true JP2023505708A5 (cg-RX-API-DMAC7.html) 2023-12-18
JP7720305B2 JP7720305B2 (ja) 2025-08-07

Family

ID=76329625

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022535591A Active JP7720305B2 (ja) 2019-12-12 2020-12-11 抗クローディン抗体薬物複合体及びその医薬用途

Country Status (10)

Country Link
US (1) US20230054458A1 (cg-RX-API-DMAC7.html)
EP (1) EP4074345A4 (cg-RX-API-DMAC7.html)
JP (1) JP7720305B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220113728A (cg-RX-API-DMAC7.html)
CN (2) CN118403182A (cg-RX-API-DMAC7.html)
AU (1) AU2020402006A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022011032A2 (cg-RX-API-DMAC7.html)
CA (1) CA3162754A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022006893A (cg-RX-API-DMAC7.html)
WO (1) WO2021115426A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021011489A (es) * 2019-04-01 2021-10-22 Jiangsu Hengrui Medicine Co Anticuerpo anti-claudina 18.2 y utilizacion del mismo.
US20230101735A1 (en) * 2020-01-22 2023-03-30 Jiangsu Hengrui Medicine Co., Ltd. Anti-trop-2 antidody-exatecan analog conjugate and medical use thereof
JP7821733B2 (ja) * 2020-01-22 2026-02-27 上海森輝医薬有限公司 エリブリン誘導体の薬物複合体、その調製方法及びその医薬的応用
CA3175048A1 (en) * 2020-03-25 2021-09-30 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Preparation method for antibody medicament conjugate
WO2022078259A1 (zh) * 2020-10-12 2022-04-21 四川百利药业有限责任公司 一种氘代的喜树碱衍生物及其抗体药物偶联物
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
CA3224492A1 (en) 2021-07-19 2023-01-26 Xiaojun Han Immunoconjugates and methods
EP4410307A4 (en) 2021-09-30 2026-05-06 Jiangsu Hengrui Pharmaceuticals Co Ltd PYRROLO BENZODIAZEPINE DERIVATIVE AND CONJUGATE, PROCESS FOR THEIR PREPARATION AND USE
CN118139876A (zh) * 2021-10-19 2024-06-04 博奥信生物技术(南京)有限公司 结合cldn18.2的抗体及其用途
JP7767613B2 (ja) 2021-11-15 2025-11-11 システィミューン,インコーポレイテッド 二重特異性抗体-カンプトテシン薬物複合体及びその製薬的使用
US11814394B2 (en) 2021-11-16 2023-11-14 Genequantum Healthcare (Suzhou) Co., Ltd. Exatecan derivatives, linker-payloads, and conjugates and thereof
AU2022416272A1 (en) * 2021-12-17 2024-07-18 Fortvita Biologics (Singapore) Pte. Ltd. Antibody-drug conjugate targeting claudin18.2
WO2024012566A2 (en) 2022-07-15 2024-01-18 Genequantum Healthcare (Suzhou) Co., Ltd. Antibody, linkers, payload, conjugates and applications thereof
CN120225528A (zh) * 2022-09-02 2025-06-27 默沙东有限责任公司 依喜替康衍生的拓扑异构酶-1抑制剂药物组合物及其用途
AU2024380559A1 (en) 2023-11-17 2026-06-04 Mersana Therapeutics, Inc. Treatment of cancer using b7-h4-targeted antibody-drug conjugates

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6504029B1 (en) 1995-04-10 2003-01-07 Daiichi Pharmaceutical Co., Ltd. Condensed-hexacyclic compounds and a process therefor
WO2003000657A1 (en) 2001-06-20 2003-01-03 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
JP2015506349A (ja) 2011-12-21 2015-03-02 アルデリックス, インコーポレイテッド 非全身性tgr5アゴニスト
CN104168899B (zh) 2012-01-13 2017-04-05 通用医疗公司 麻醉剂化合物及其相关的使用方法
US10195288B2 (en) 2012-10-11 2019-02-05 Daiichi Sankyo Company, Limited Antibody-drug conjugate
SG11201603960XA (en) 2014-01-31 2016-07-28 Daiichi Sankyo Co Ltd Anti-her2 antibody-drug conjugate
WO2016165762A1 (en) 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
CN108101825B (zh) * 2016-11-25 2022-02-22 迈威(上海)生物科技股份有限公司 用于抗体-药物偶联的双取代马来酰胺类连接子及其制备方法和用途
CN109106951A (zh) * 2017-08-18 2019-01-01 四川百利药业有限责任公司 一种喜树碱-抗体偶联物
EP3794042B1 (en) 2018-05-18 2024-03-27 Daiichi Sankyo Co., Ltd. Anti-muc1- exatecan antibody-drug conjugate
EP3808376A4 (en) * 2018-06-17 2021-09-01 L&L Biopharma Co., Ltd. CLDN18.2 ANTIBODY, BISPECIFIC ANTIBODY, ADC AND CAR, AND APPLICATIONS THEREOF
CN111110862A (zh) * 2018-11-01 2020-05-08 上海健信生物医药科技有限公司 抗cldn18.2抗体的药物偶联体及其制备方法和用途
UA130338C2 (uk) * 2018-09-26 2026-01-28 Джянгсу Хенгруй Медісін Ко., Лтд. Кон'югат ліганд-лікарський засіб аналога ексатекану, спосіб його отримання та його застосування
JP7408646B2 (ja) * 2018-09-30 2024-01-05 ジエンス ハンソー ファーマスーティカル グループ カンパニー リミテッド 抗-b7h3抗体-エキサテカンアナログコンジュゲート及びその医薬用途
CN109762067B (zh) * 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
MX2021011489A (es) * 2019-04-01 2021-10-22 Jiangsu Hengrui Medicine Co Anticuerpo anti-claudina 18.2 y utilizacion del mismo.
CN111689980A (zh) * 2019-05-26 2020-09-22 四川百利药业有限责任公司 一种喜树碱药物及其抗体偶联物
AU2020288275A1 (en) * 2019-06-06 2022-02-03 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Anti-B7-H4 antibody–drug conjugate and medicinal use thereof
WO2020259258A1 (zh) * 2019-06-28 2020-12-30 上海复旦张江生物医药股份有限公司 一种抗体偶联药物、其中间体、制备方法及应用
AU2021354827A1 (en) * 2020-09-30 2023-06-01 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition comprising antibody-drug conjugate, and use of pharmaceutical composition

Similar Documents

Publication Publication Date Title
JP2023510905A5 (cg-RX-API-DMAC7.html)
TWI869913B (zh) 吡啶并[4,3-d]嘧啶化合物
CN111377871B (zh) 一种fak抑制剂及其联合用药物
JP2023506805A5 (cg-RX-API-DMAC7.html)
WO2024218686A1 (en) Pyrido[4,3-d]pyrimidine compounds
ES2779152T3 (es) Derivados de (2-(5-isoindolin-2-il)pirimidin-4-il)-amina como inhibidores de Rho-quinasa para tratar enfermedades autoinmunes
CA3168654A1 (en) Drug conjugate of eribulin derivative, preparation method therefor and application thereof in medicine
BR112021004829A2 (pt) conjugado de anticorpo anti-b7h3-análogo de exatecano e uso medicinal do mesmo
JP2023519261A5 (cg-RX-API-DMAC7.html)
TW202144015A (zh) B7h3抗體-依喜替康類似物偶聯物及其醫藥用途
JP2022511351A5 (cg-RX-API-DMAC7.html)
EP3678700B1 (en) Compounds for reducing the viscosity of biological formulations
TW202108181A (zh) 抗trop2抗體及其生產方法、及抗trop2抗體-藥物結合物
KR20250100539A (ko) 피리도[4,3-d]피리미딘 화합물
CN116096896A (zh) 一种含抗体药物偶联物的药物组合物及其用途
CN111617078B (zh) 用于疾病治疗和/或预防的药物组合物、方法及其用途
CA2944255C (en) New derivatives of cephalosporin for treating cancer
KR20220167275A (ko) 암 치료 방법
JP2024545138A (ja) 親和性が改善された抗体薬物複合体、その調製法、及びその応用
JP2024536798A5 (cg-RX-API-DMAC7.html)
RU2022125170A (ru) Конъюгат антитела против PSMA и аналога эксатекана и его медицинское применение
CN120554370A (zh) 一种抗体-药物偶联物及其制备方法和用途
HK40117290A (en) Pyrido[4,3-d]pyrimidine compounds
WO2025231223A1 (en) Wee1 inhibitor combination therapy
WO2023044016A2 (en) Antibody immune-stimulant conjugates and use thereof